Red X iconGreen tick iconYellow tick icon

Di Leishman Research Midwife


Di has been a Registered Comprehensive nurse since 1983 and a Registered Midwife since 1998.

She is passionate about midwifery and the health of mothers and babies, and has worked in a variety of settings and roles including lead maternity carer, core midwife, midwifery educator in quality improvements, and has been the Canterbury Perinatal Mortality Review coordinator since 2010.

Di has a Post graduate Diploma in Midwifery from Otago University (2015), and has been employed by Otago University since 2010 as research midwife, currently work 0.5FTE co-ordinating multi-centred clinical trials which include:

  • APTS Australian Placental Transfusion Study (Sydney)
  • MAGENTA Magnesium Sulphate at 30 to 34 weeks gestational age: Neuroprotection (Adelaide)
  • MAGNUM MRI investigation at term for MAGENTA recruits (Auckland)
  • STRIDER A randomised controlled trial of sildenafil therapy in dismal prognosis early onset intrauterine growth restriction (Auckland)
  • TARGET Optimal Glycaemic targets for Gestational Diabetes (Auckland)
  • RSV vaccine in pregnancy study: "Does Respiratory Syncytial Virus vaccine in pregnancy protect babies against lung disease?" (USA)
  • MBM My Baby Movements Trial (Brisbane)


Crowther, C. A., Ashwood, P., Middleton, P. F., McPhee, A., Tan, T., Harding, J. E., for the MAGENTA Study Group, including Austin, N., Darlow, B. A., Dixon, B., Gullam, J., Leishman, D., Dawson, P., Devenish, C., Gaerty, K., Tomlinson, P. A., & Miller, H. (2023). Prenatal intravenous magnesium at 30-34 weeks' gestation and neurodevelopmental outcomes in offspring: The MAGENTA randomized clinical trial. JAMA, 330(7), 603-614. doi: 10.1001/jama.2023.12357

Tarnow-Mordi, W. O., Robledo, K., Marschner, I., Seidler, L., Simes, J., on behalf of the Australian Placental Transfusion Study (APTS) Childhood Follow Up Study Collaborators, including Gullam, J., Austin, N., Leishman, D., Stitely, M., & Dawson, P. (2023). To guide future practice, perinatal trials should be much larger, simpler and less fragile with close to 100% ascertainment of mortality and other key outcomes. Seminars in Perinatology, 47(5), 151789. doi: 10.1016/j.semperi.2023.151789

Back to top